Author:
OncoTherics second annual general meeting was held on 30th June 2023 and the FY2022 audited accounts were approved. The company looks forward to progressing its preclinical toxicology programme in 2023/2024 with exciting developments for fast tracking OCT1002 into the clinic.
OncoTherics is currently raising first round funding. If you are interested in taking part, please provide your contact details so that we can include you on our contact list.
Are you working on a project where OncoTherics' technology might be of help or would you like to collaborate in our research? Please provide your contact details so that we can include you on our contact list.